Literature DB >> 10215945

Tolerance induction using the Malmö treatment model 1982-1995.

C Freiburghaus1, E Berntorp, M Ekman, M Gunnarsson, B Kjellberg, I M Nilsson.   

Abstract

The ultimate goal in the treatment of haemophilia patients with inhibitors is to eradicate permanently the inhibitor and induce tolerance. Here we summarize our experience at the Malmö centre regarding tolerance induction according to the Malmö Treatment Model. The protocol includes immunoadsorption if needed, neutralization of inhibitor and replacement with factor concentrates, cyclophosphamide intravenously for 2 days (12-15 mg kg-1 bw) and then orally (2-3 mg kg-1 bw) for an additional 8-10 days and intravenous gammaglobulin daily at dosages of 0.4 g kg-1 bw for 5 days. This protocol has been applied in 23 haemophilia patients with inhibitors, 16 haemophilia A patients and seven haemophilia B patients. Altogether 36 attempts have been made to induce tolerance. Ten of the 16 haemophilia A (62.5%) and 6/7 patients with haemophilia B (86%) became tolerant after the treatment. The chances of success or failure are roughly equal, if the series is considered in a historical perspective. The data showed that the chances of success in tolerance induction with the Malmö protocol were best in those patients with low inhibitor titres, with relatively low historical inhibitory peak and with a long interval since the previous replacement therapy. This was especially true where no inflammatory state was present at the start or during tolerance induction. The advantage with this method compared to the high-dose regimen is that in the successful cases tolerance can be achieved within 3-4 weeks.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10215945     DOI: 10.1046/j.1365-2516.1999.00195.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  10 in total

1.  Plasma exchange and immunosuppressive therapy in a case of mild haemophilia A with inhibitors and a life-threatening lower limb haemorrhage.

Authors:  Chiara Ambaglio; Fabio Lodo; Alice Trinchero; Nicola Ghidelli; Cesare Perotti; Claudia Del Fante; Gabriella Gamba
Journal:  Blood Transfus       Date:  2013-01-02       Impact factor: 3.443

Review 2.  Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 3.  Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives.

Authors:  Zera Tellier; Marie-Hélène André; Benoît Polack
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

Review 4.  Management of factor VIII inhibitors.

Authors:  Donna M Dimichele
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

5.  Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.

Authors:  Yoko Mizoguchi; Aya Furue; Reiko Kagawa; Ikue Chijimatsu; Keita Tomioka; Maiko Shimomura; Yusuke Imanaka; Shiho Nishimura; Satoshi Saito; Mizuka Miki; Atsushi Ono; Nakao Konishi; Hiroshi Kawaguchi; Masao Kobayashi
Journal:  Int J Hematol       Date:  2016-02-01       Impact factor: 2.490

6.  Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran.

Authors:  Hamid Reza Rasekh; Ali Imani; Mehran Karimi; Mina Golestani
Journal:  Clinicoecon Outcomes Res       Date:  2011-11-23

Review 7.  octanate®: over 20 years of clinical experience in overcoming challenges in haemophilia A treatment.

Authors:  Anna Klukowska; Vladimír Komrska; Vladimír Vdovin; Nadezhda Zozulya; Toshko Lissitchkov; Johannes Oldenburg; Carmen Escuriola Ettingshausen
Journal:  Ther Adv Hematol       Date:  2020-04-19

Review 8.  Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.

Authors:  Rolf Ljung; Guenter Auerswald; Gary Benson; Gerry Dolan; Anne Duffy; Cedric Hermans; Victor Jiménez-Yuste; Thierry Lambert; Massimo Morfini; Silva Zupančić-Šalek; Elena Santagostino
Journal:  Eur J Haematol       Date:  2018-12-06       Impact factor: 2.997

9.  Clinical Care of Bone Health in Patients on the Immune Tolerance Induction's Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia.

Authors:  Zahra Rezaieyazdi; Hassan Mansouritorghabeh
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

10.  Final Results of the Prospective ADVATE® Immune Tolerance Induction Registry (PAIR) Study with Plasma- and Albumin-Free Recombinant Factor VIII.

Authors:  Amy D Shapiro; Alejandro Fernandez; Jerome Teitel; Jaco Botha; Kate Khair
Journal:  J Blood Med       Date:  2021-11-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.